GlobeNewswire Inc.··Ars Pharmaceuticals, Inc.ARS Pharmaceuticals Posts $22.7M Q1 Revenue as Neffy Sales Surge, But Losses Widen
ARS Pharmaceuticals reported Q1 2026 revenue of $22.7M driven by Neffy epinephrine spray sales, though net losses reached $60.6M amid expansion efforts.
SPRYchronic spontaneous urticariaFDA approval